188 related articles for article (PubMed ID: 37064291)
21. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
22. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
23. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.
D'Huyvetter M; Aerts A; Xavier C; Vaneycken I; Devoogdt N; Gijs M; Impens N; Baatout S; Ponsard B; Muyldermans S; Caveliers V; Lahoutte T
Contrast Media Mol Imaging; 2012; 7(2):254-64. PubMed ID: 22434639
[TBL] [Abstract][Full Text] [Related]
24. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
25. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
26. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
[TBL] [Abstract][Full Text] [Related]
27. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
28. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
[TBL] [Abstract][Full Text] [Related]
31. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
32. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
[TBL] [Abstract][Full Text] [Related]
33. Preparation and preclinical evaluation of
Kameswaran M; Gota V; Ambade R; Gupta S; Dash A
J Labelled Comp Radiopharm; 2017 Jan; 60(1):12-19. PubMed ID: 27813128
[TBL] [Abstract][Full Text] [Related]
34. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
[TBL] [Abstract][Full Text] [Related]
35. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
37. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
Feng Y; Meshaw R; Zhao XG; Jannetti S; Vaidyanathan G; Zalutsky MR
J Nucl Med; 2023 Jan; 64(1):124-130. PubMed ID: 35618478
[TBL] [Abstract][Full Text] [Related]
38. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
39. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
40. Labeling a TCO-functionalized single domain antibody fragment with
Zhou Z; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]